Provided are triazolopyridine derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include 2-Methyl-4-(pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-amide and 2-Methyl-4-(pyrrolidine-1-carbonyl)-2H-pyrazole-3-carboxylic acid [2-(3-methoxypyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-amide. The compounds are phosphodiesterase 10A (PDE10A) inhibitors. The compounds may be useful in the treatment of cancer and neurological disorders.
